|
May 14
|
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
|
|
May 14
|
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
|
|
May 13
|
One stock is dragging down the S&P 500's earnings growth
|
|
May 9
|
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
|
May 9
|
Gilead's FOCUS Program Helps Zero In on Early HIV Detection
|
|
May 9
|
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight
|
|
May 7
|
Gilead Helps Put African Nation on Path To Eliminate Hepatitis C
|
|
May 7
|
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
|
|
May 6
|
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
|
|
May 4
|
23 Most Profitable Stocks of the Last 12 Months
|
|
May 3
|
Forbes Has Listed Gilead as One of America’s Best Employers for Diversity
|
|
May 3
|
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
|
|
May 2
|
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
|
|
May 1
|
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar
|
|
Apr 30
|
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
|
|
Apr 29
|
Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data
|
|
Apr 27
|
Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Apr 26
|
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
|
|
Apr 26
|
Q1 2024 Gilead Sciences Inc Earnings Call
|
|
Apr 26
|
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
|